{"protocolSection": {"identificationModule": {"nctId": "NCT03152084", "orgStudyIdInfo": {"id": "D1690C00049"}, "secondaryIdInfos": [{"id": "2016-002961-79", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.", "officialTitle": "DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function", "acronym": "DAPASALT"}, "statusModule": {"statusVerifiedDate": "2021-05", "overallStatus": "TERMINATED", "whyStopped": "Poor recruitment.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-07-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-03-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-03-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-04-18", "studyFirstSubmitQcDate": "2017-05-11", "studyFirstPostDateStruct": {"date": "2017-05-12", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-03-17", "resultsFirstSubmitQcDate": "2021-05-25", "resultsFirstPostDateStruct": {"date": "2021-05-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-05-25", "lastUpdatePostDateStruct": {"date": "2021-05-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2", "Kidney Function Tests"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 24, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1", "type": "EXPERIMENTAL", "description": "T2DM subjects with an eGFR (CKD-EPI) between \u226525 and \u226450 mL/min/1.73m2 at the Screening Visit.", "interventionNames": ["Drug: Dapagliflozin"]}, {"label": "Arm 2", "type": "EXPERIMENTAL", "description": "T2DM subjects with an eGFR (CKD-EPI) between \\>90 and \u2264130 mL/min/1.73m2 for patients aged 59 or younger, between \\>85 and \u2264130 mL/min/1.73m2 for patients aged 60 to 69, and between \\>75 and \u2264130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.", "interventionNames": ["Drug: Dapagliflozin"]}, {"label": "Arm 3", "type": "EXPERIMENTAL", "description": "Non-diabetic subjects with an eGFR (CKD-EPI) between \u226525 and \u226450 mL/min/1.73m2 at the Screening Visit.", "interventionNames": ["Drug: Dapagliflozin"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.", "armGroupLabels": ["Arm 1", "Arm 2", "Arm 3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in 24-hour Sodium Excretion From Baseline to Start of Treatment", "description": "Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.", "timeFrame": "From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)"}], "secondaryOutcomes": [{"measure": "Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up", "description": "Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).", "timeFrame": "From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)"}, {"measure": "Change in 24-hour Glucose Excretion From Baseline to Start of Treatment", "description": "Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).", "timeFrame": "From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)"}, {"measure": "Change in 24-hour Glucose Excretion From Baseline to End of Treatment", "description": "Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)", "timeFrame": "From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)"}, {"measure": "Change in 24-hour Glucose Excretion From End of Treatment to Follow-up", "description": "Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).", "timeFrame": "From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)"}, {"measure": "Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment", "description": "Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)", "timeFrame": "From baseline (Day -1) to start of treatment (Day 4)"}, {"measure": "Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment", "description": "Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).", "timeFrame": "From baseline (Day -1) to end of treatment (Day 13)"}, {"measure": "Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up", "description": "Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).", "timeFrame": "From end of treatment (Day 13) to end of follow-up (Day 18)"}, {"measure": "Change in Plasma Volume From Baseline to Start of Treatment", "description": "Change in plasma volume from baseline to start of treatment (Day 4).", "timeFrame": "From baseline (Day 1) to start of treatment (Day 4)"}, {"measure": "Change in Plasma Volume From Baseline to End of Treatment", "description": "Change in plasma volume from baseline to end of treatment (Day 14).", "timeFrame": "From baseline (Day 1) to end of treatment (Day 14)"}, {"measure": "Change in Plasma Volume From End of Treatment to End of Follow-up", "description": "Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).", "timeFrame": "From end of treatment (Day 14) to end of follow-up (Day 18)"}, {"measure": "Change in Extracellular Volume From Baseline to Start of Treatment", "description": "Change in extracellular volume from baseline to start of treatment (Day 4).", "timeFrame": "From baseline (Day 1) to start of treatment (Day 4)"}, {"measure": "Change in Extracellular Volume From Baseline to End of Treatment", "description": "Change in extracellular volume from baseline to end of treatment (Day 14).", "timeFrame": "From baseline (Day 1) to end of treatment (Day 14)"}, {"measure": "Change in Extracellular Volume From End of Treatment to End of Follow-up", "description": "Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).", "timeFrame": "From end of treatment (Day 14) to end of follow-up (Day 18)"}, {"measure": "Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)", "description": "Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).", "timeFrame": "From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)"}, {"measure": "Pharmacokinetics of Dapagliflozin on Day 4 and Day 14", "description": "Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)", "timeFrame": "At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)"}, {"measure": "Number of Patients With AEs and SAEs", "description": "An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.", "timeFrame": "From Day 1 until Day 18 (Follow-up)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of signed and dated, written informed consent prior to any study specific procedures\n* Female and/or male aged between 18 years and \u226480 years\n* In the diabetic arms - a diagnosis of T2DM with HbA1c \u22656.5% (\u226548 mmol/mol) and \\<10% (\\<86 mmol/mol); and eGFR (CKD-EPI) between \u226525 and \u226450 mL/min/1.73m2 or between \\>90 and \u2264130 mL/min/1.73m2 for patients aged 59 years or younger, between \\>85 and \u2264130 mL/min/1.73m2 for patients aged 60 to 69 years, and between \\>75 and \u2264130 mL/min/1.73m2 for patients aged 70 years or older at the Screening Visit (Visit 1)\n* In the non-diabetic arm, HbA1c \\<6.5% (\\<48 mmol/mol) and an eGFR (CKD-EPI) between \u226525 and \u226450 mL/min/1.73m2 at the Screening Visit (Visit 1)\n* Patient specific optimal antihypertensive dose of an angiotensin receptor blocker at least 6 weeks before study treatment\n* In the diabetic arm (Group 2) an appropriate stable dose of metformin, or sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks before study treatment\n* Stable urinary sodium excretion on 2 successive 24-hr urinary sodium excretion measurements.\n* In the diabetic arm with impaired renal function (Group 1), a stable insulin dosing (intermediate, long-acting, premixed insulin, basal bolus insulin) for the last 12 weeks prior to Visit 4 (Day 1), as judged by the Investigator. Metformin or sulphonylurea, or metformin+sulphonylurea together with insulin would be accepted, but is not mandatory. If used, stable dose of metformin or sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks prior to Visit 4 (Day 1) is required.\n\nExclusion Criteria:\n\n* Diagnosis of Type 1 Diabetes Mellitus\n* Any of the following cardiovascular/vascular diseases within 3 months prior to signing the consent; myocardial infarction, cardiac surgery or revascularization, unstable angina, unstable heart failure, heart failure NYHA Class IV, transient ischemic attack or significant cerebrovascular disease, unstable or previously undiagnosed arrhythmia\n* Symptoms/complaints suggestive of established neurogenic bladder and/or incomplete bladder emptying\n* History of bladder cancer, diagnosis of polycystic kidney disease, history or current lupus nephritis or unstable or rapidly progressing renal disease\n* UACR \\>1000 mg/g at screening\n* Current/chronic use of the following medications: any anti-diabetic medication with the exception of metformin, sulphonylurea, angiotensin converting enzyme inhibitors, insulin (insulin only allowed in Group 1), oral glucocorticoids, non-steroidal anti-inflammatory drugs, immune suppressants, chemotherapeutics, antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors\n* Receiving immunosuppressive or other immunotherapy for primary or secondary renal disease within 6 months prior to screening\n* Current treatment or treatment within the last 2 weeks prior to screening with diuretics including loop diuretics, thiazides, and mineralocorticoid antagonists", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Almelo", "zip": "7609 PP", "country": "Netherlands", "geoPoint": {"lat": 52.35667, "lon": 6.6625}}, {"facility": "Research Site", "city": "Amsterdam", "zip": "1081 HV", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"facility": "Research Site", "city": "Stockholm", "zip": "14186", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Research Site", "city": "\u00d6rebro", "zip": "70185", "country": "Sweden", "geoPoint": {"lat": 59.27412, "lon": 15.2066}}]}, "referencesModule": {"references": [{"pmid": "35570989", "type": "DERIVED", "citation": "Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Hammarstedt A, Karlsson C, Hallow KM, Danser AHJ, Heerspink HJL, van Raalte DH. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet. Kidney Int Rep. 2022 Mar 4;7(5):1084-1092. doi: 10.1016/j.ekir.2022.02.023. eCollection 2022 May."}, {"pmid": "33318125", "type": "DERIVED", "citation": "Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJL. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care. 2021 Feb;44(2):440-447. doi: 10.2337/dc20-2604. Epub 2020 Dec 14."}], "seeAlsoLinks": [{"label": "Redacted CSP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1690C00049&amp;attachmentIdentifier=be370583-b4a1-4b70-beb9-36494cdc972e&amp;fileName=D1690C00049_Redacted_CSP.pdf&amp;versionIdentifier="}, {"label": "Redacted SAP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1690C00049&amp;attachmentIdentifier=c44b2c01-34f0-4182-ab6f-d195ab6b4d61&amp;fileName=D1690C00049_Redacted_SAP.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All study assessments were performed as per the schedule of assessment. No patients in Group 1 were enrolled into the Run-in set due to failure to meet inclusion exclusion criteria, screen failure, or other reasons. Due to unsatisfactory recruitment rate, it was decided that no more Group 1 patients would be enrolled in the study. Group 1 included type 2 diabetes mellitus (T2DM) patients with impaired kidney function and were to receive oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14.", "recruitmentDetails": "The study was conducted between 12-Jul-2017 and 20-Mar-2020. Patients who met all the inclusion and none of the exclusion criteria were enrolled in the study.", "groups": [{"id": "FG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "FG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Set: All patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.", "groups": [{"id": "BG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "BG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "24"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<=18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Between 18 and 80 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "24"}]}]}, {"title": ">=80 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "23"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in 24-hour Sodium Excretion From Baseline to Start of Treatment", "description": "Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmol/24 hour", "timeFrame": "From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.33", "lowerLimit": "-53.667", "upperLimit": "44.000"}, {"groupId": "OG001", "value": "-27.67", "lowerLimit": "-69.334", "upperLimit": "13.334"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.4462", "pValueComment": "Start of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-5.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.542", "ciUpperLimit": "9.120"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up", "description": "Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmol/24 hour", "timeFrame": "From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "End of treatment vs baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.67", "lowerLimit": "-64.000", "upperLimit": "143.167"}, {"groupId": "OG001", "value": "-23.83", "lowerLimit": "-107.000", "upperLimit": "0.667"}]}]}, {"title": "Follow-up vs end of treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.33", "lowerLimit": "-135.334", "upperLimit": "25.000"}, {"groupId": "OG001", "value": "6.17", "lowerLimit": "-70.333", "upperLimit": "20.333"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.7842", "pValueComment": "End of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "3.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.817", "ciUpperLimit": "32.195"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0581", "pValueComment": "Follow-up vs End of treatment", "statisticalMethod": "Regression, Linear", "paramType": "Least square mean", "paramValue": "-16.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.109", "ciUpperLimit": "0.664"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Glucose Excretion From Baseline to Start of Treatment", "description": "Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmol/24 hour", "timeFrame": "From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "302.61", "lowerLimit": "191.472", "upperLimit": "635.726"}, {"groupId": "OG001", "value": "43.93", "lowerLimit": "12.050", "upperLimit": "132.333"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "<0.0001", "pValueComment": "Start of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "344.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "272.785", "ciUpperLimit": "416.905"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Glucose Excretion From Baseline to End of Treatment", "description": "Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmol/24 hour", "timeFrame": "From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "283.40", "lowerLimit": "155.876", "upperLimit": "762.801"}, {"groupId": "OG001", "value": "29.88", "lowerLimit": "15.450", "upperLimit": "113.300"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "<0.0001", "pValueComment": "End of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "311.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "224.528", "ciUpperLimit": "398.064"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Glucose Excretion From End of Treatment to Follow-up", "description": "Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmol/24 hour", "timeFrame": "From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-168.43", "lowerLimit": "-376.561", "upperLimit": "-107.596"}, {"groupId": "OG001", "value": "-37.02", "lowerLimit": "-74.733", "upperLimit": "-10.584"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "<0.0001", "pValueComment": "Follow-up vs end of treatment", "statisticalMethod": "Regression, Linear", "paramType": "Least square mean", "paramValue": "-203.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-235.983", "ciUpperLimit": "-170.162"}]}, {"type": "SECONDARY", "title": "Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment", "description": "Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmHg", "timeFrame": "From baseline (Day -1) to start of treatment (Day 4)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.4810", "lowerLimit": "-13.6610", "upperLimit": "5.6100"}, {"groupId": "OG001", "value": "-8.9730", "lowerLimit": "-24.6570", "upperLimit": "2.7210"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0047", "pValueComment": "Start of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-5.2658", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.5459", "ciUpperLimit": "-1.9856"}]}, {"type": "SECONDARY", "title": "Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment", "description": "Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmHg", "timeFrame": "From baseline (Day -1) to end of treatment (Day 13)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.9385", "lowerLimit": "-16.0060", "upperLimit": "0.9160"}, {"groupId": "OG001", "value": "-10.3290", "lowerLimit": "-23.4160", "upperLimit": "16.2160"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0003", "pValueComment": "End of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-7.0987", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.0379", "ciUpperLimit": "-4.1595"}]}, {"type": "SECONDARY", "title": "Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up", "description": "Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mmHg", "timeFrame": "From end of treatment (Day 13) to end of follow-up (Day 18)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.5140", "lowerLimit": "-10.3420", "upperLimit": "8.4590"}, {"groupId": "OG001", "value": "-2.6590", "lowerLimit": "-16.3110", "upperLimit": "7.4680"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.5592", "pValueComment": "Follow-up vs end of treatment", "statisticalMethod": "Regression, Linear", "paramType": "Least square mean", "paramValue": "0.7287", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.9894", "ciUpperLimit": "3.4468"}]}, {"type": "SECONDARY", "title": "Change in Plasma Volume From Baseline to Start of Treatment", "description": "Change in plasma volume from baseline to start of treatment (Day 4).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Litres", "timeFrame": "From baseline (Day 1) to start of treatment (Day 4)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1440", "lowerLimit": "-1.7819", "upperLimit": "2.6385"}, {"groupId": "OG001", "value": "-0.1139", "lowerLimit": "-2.0340", "upperLimit": "0.0232"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.9288", "pValueComment": "Start of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "0.0315", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.7274", "ciUpperLimit": "0.7904"}]}, {"type": "SECONDARY", "title": "Change in Plasma Volume From Baseline to End of Treatment", "description": "Change in plasma volume from baseline to end of treatment (Day 14).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Litres", "timeFrame": "From baseline (Day 1) to end of treatment (Day 14)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2122", "lowerLimit": "-2.8346", "upperLimit": "1.1073"}, {"groupId": "OG001", "value": "2.0557", "lowerLimit": "2.0557", "upperLimit": "2.0557"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.1659", "pValueComment": "End of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-0.4318", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.0761", "ciUpperLimit": "0.2125"}]}, {"type": "SECONDARY", "title": "Change in Plasma Volume From End of Treatment to End of Follow-up", "description": "Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Litres", "timeFrame": "From end of treatment (Day 14) to end of follow-up (Day 18)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6464", "lowerLimit": "-1.5016", "upperLimit": "1.6410"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0190", "pValueComment": "Follow-up vs end of treatment", "statisticalMethod": "Regression, Linear", "paramType": "Least square mean", "paramValue": "0.4755", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0963", "ciUpperLimit": "0.8548"}]}, {"type": "SECONDARY", "title": "Change in Extracellular Volume From Baseline to Start of Treatment", "description": "Change in extracellular volume from baseline to start of treatment (Day 4).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Litres", "timeFrame": "From baseline (Day 1) to start of treatment (Day 4)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5783", "lowerLimit": "-2.7027", "upperLimit": "0.7959"}, {"groupId": "OG001", "value": "-0.4553", "lowerLimit": "-1.3758", "upperLimit": "0.2282"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0157", "pValueComment": "Start of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-0.6713", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1914", "ciUpperLimit": "-0.1511"}]}, {"type": "SECONDARY", "title": "Change in Extracellular Volume From Baseline to End of Treatment", "description": "Change in extracellular volume from baseline to end of treatment (Day 14).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Litres", "timeFrame": "From baseline (Day 1) to end of treatment (Day 14)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1248", "lowerLimit": "-1.4948", "upperLimit": "0.9852"}, {"groupId": "OG001", "value": "-0.1427", "lowerLimit": "-0.6101", "upperLimit": "1.0055"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.8700", "pValueComment": "End of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-0.0324", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4631", "ciUpperLimit": "0.3984"}]}, {"type": "SECONDARY", "title": "Change in Extracellular Volume From End of Treatment to End of Follow-up", "description": "Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Litres", "timeFrame": "From end of treatment (Day 14) to end of follow-up (Day 18)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1784", "lowerLimit": "-0.6507", "upperLimit": "0.9780"}, {"groupId": "OG001", "value": "0.1394", "lowerLimit": "-0.3045", "upperLimit": "0.9014"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.2446", "pValueComment": "Follow-up vs end of treatment", "statisticalMethod": "Regression, Linear", "paramType": "Least square mean", "paramValue": "0.1718", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1358", "ciUpperLimit": "0.4795"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)", "description": "Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).", "populationDescription": "Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "mg/mmol", "timeFrame": "From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "Start of treatment vs baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "lowerLimit": "-30.750", "upperLimit": "6.700"}, {"groupId": "OG001", "value": "-5.83", "lowerLimit": "-35.300", "upperLimit": "0.300"}]}]}, {"title": "End of treatment vs baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "lowerLimit": "-17.250", "upperLimit": "0.737"}, {"groupId": "OG001", "value": "-7.28", "lowerLimit": "-35.733", "upperLimit": "0.467"}]}]}, {"title": "Follow-up vs end of treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "lowerLimit": "-0.243", "upperLimit": "51.667"}, {"groupId": "OG001", "value": "-0.19", "lowerLimit": "-2.967", "upperLimit": "6.367"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0023", "pValueComment": "Start of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-2.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.299", "ciUpperLimit": "-0.902"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "<0.0001", "pValueComment": "End of treatment vs baseline", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean", "paramValue": "-1.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.929", "ciUpperLimit": "-1.256"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Within-group change", "pValue": "0.0002", "pValueComment": "Follow-up vs end of treatment", "statisticalMethod": "Regression, Linear", "paramType": "Least square mean", "paramValue": "3.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.215", "ciUpperLimit": "5.553"}]}, {"type": "SECONDARY", "title": "Pharmacokinetics of Dapagliflozin on Day 4 and Day 14", "description": "Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)", "populationDescription": "Pharmacokinetic analysis set: all patients who were dispensed at least one dose of the study drug and for whom at least one of the plasma concentration samples were available and who had no important protocol deviations judged to impact the analysis of the PK data. Here, number analyzed in each row signifies only the patients with available data that were analyzed for that specified time point.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"title": "Day 4, Pre-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.58", "spread": "134.88"}, {"groupId": "OG001", "value": "19.78", "spread": "116.54"}]}]}, {"title": "Day 14, Pre-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.54", "spread": "46.60"}, {"groupId": "OG001", "value": "15.26", "spread": "41.97"}]}]}, {"title": "Day 14, 1 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.46", "spread": "110.66"}, {"groupId": "OG001", "value": "63.83", "spread": "150.41"}]}]}, {"title": "Day 14, 2 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46.47", "spread": "49.30"}, {"groupId": "OG001", "value": "60.41", "spread": "140.69"}]}]}, {"title": "Day 14, 4 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.71", "spread": "47.38"}, {"groupId": "OG001", "value": "47.83", "spread": "100.41"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With AEs and SAEs", "description": "An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.", "populationDescription": "Safety set: all patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "From Day 1 until Day 18 (Follow-up)", "groups": [{"id": "OG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}, {"id": "OG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "AEs judged as causally related to dapagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "AEs leading to death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "SAEs (including outcomes = death)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "SAEs causally related to dapagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "AEs leading to permanent discontinuation of dapagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "SAEs leading to permanent discontinuation of dapagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hypoglycaemia AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hypoglycaemia AEs leading to permanent discontinuation of dapagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Day 1 until Day 18 (FU)", "description": "SAEs and non-SAEs are reported for the Safety Set which comprised of all patients who received at least one dose of study drug and who had data from at least one post-dose safety assessment available.", "eventGroups": [{"id": "EG000", "title": "Group 2", "description": "Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.", "deathsNumAffected": 0, "deathsNumAtRisk": 17, "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 6, "otherNumAtRisk": 17}, {"id": "EG001", "title": "Group 3", "description": "Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 2, "otherNumAtRisk": 7}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Genital infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}]}, {"term": "Head discomfort", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Dry skin", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 7}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was prematurely closed due to unsatisfactory recruitment rate. Of 5 patients enrolled in the Group 1, none were enrolled into the Run-in set due to failure to meet inclusion/exclusion criteria, screen failure, withdrawal or other reason and hence it was decided that no more Group 1 patients would be enrolled in the study. In Group 2 and 3, 17 and 7 patients received the investigational product and completed the study, respectively."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Study results are Sponsor's intellectual property and PIs cannot present or publish results without prior Sponsor approval."}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca Clinical Study Information Center", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-01-10", "uploadDate": "2021-03-17T09:51", "filename": "Prot_000.pdf", "size": 1924955}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-10-25", "uploadDate": "2021-03-17T09:51", "filename": "SAP_001.pdf", "size": 1268960}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000051437", "term": "Renal Insufficiency"}, {"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000007674", "term": "Kidney Diseases"}, {"id": "D000014570", "term": "Urologic Diseases"}, {"id": "D000052776", "term": "Female Urogenital Diseases"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000052801", "term": "Male Urogenital Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M26718", "name": "Renal Insufficiency", "asFound": "Impaired Renal Function", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M10698", "name": "Kidney Diseases", "relevance": "LOW"}, {"id": "M17319", "name": "Urologic Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "M27095", "name": "Male Urogenital Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}